Clinical Correlates Of Sleep Problems In Systemic Sclerosis: The Prominent Role Of Pain PDF Print E-mail
Sunday, 16 January 2011 21:39
Objective. Problems with sleep are common in patients with SSc and impact daily function. Little research, however, has examined factors associated with sleep disruption in SSc. Therefore, the objective of this study was to investigate socio-demographic and medical factors associated with sleep disruption in SSc.

Methods. Cross-sectional study of 70 patients from one Canadian Scleroderma Research Group site who were assessed with a 100-mm sleep disruption visual analogue scale (VAS). Patients also completed measures of pain and depressive symptoms and underwent clinical histories and medical examinations. Pearson’s correlations were used to assess bivariate association of socio-demographic and medical variables with sleep VAS scores. Multivariable associations of socio-demographic (Step 1) and medical (Step 2) variables with sleep VAS scores were assessed using hierarchical multiple linear regression.

Results. The mean (S.D.) sleep disruption VAS score was 38.5 (29.9). In bivariate analyses, sleep disruption was associated with marital status (r =0.24, P = 0.042), smoking (r = 0.27, P = 0.025), gastrointestinal symptoms (r = 0.27, P = 0.023), breathing problems (r = 0.31, P = 0.009), pain (r = 0.53, P<0.001) and symptoms of depression (r = 0.34, P = 0.004). In multivariate analysis, only marital status (standardized  =0.24, P = 0.049) and pain (standardized  = 0.50, P<0.001) were significantly associated with sleep disruption.

Conclusion. Sleep disruption scores were as high in SSc as in RA and higher than in the general population. Pain was robustly associated with sleep disruption. Additional research is needed on sleep in SSc so that well-informed sleep interventions can be developed and tested.

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Rheumatic Autoimmune Diseases: A Local Perspective

Arguably one of the more exciting presentations delivered at the recently concluded , local Rheumatologist Dr. Haramnauth Dyaanand of the Gulf View Medical Centre, delved excitedly into the local context for autoimmune diseases. Starting off largely...

» Multidisciplinary Therapy May Improve Systemic Sclerosis

For patients with (SSc), a multidisciplinary program offers better improvement of grip strength, maximal mouth opening (MMO), six-minute walk distance (6MWD), and SSc Health Assessment Questionnaire (HAQ) score than regular outpatient care,...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Children Get Scleroderma Too

Juvenile is a rare childhood condition characterized by fibrosis of the skin and internal organs. Clinical manifestations of childhood Scleroderma are different from adult disease and early recognition, correct classification and treatment can...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...

» Gene Profiling of Scleroderma Skin Reveals Robust Signatures of Disease...

Humphrey Gardner, Jeffrey R. Shearstone, Raj Bandaru, Tom Crowell, Matthew Lynes, Maria Trojanowska, Jaspreet Pannu, Edwin Smith, Stefania Jablonska, Maria Blaszczyk, Filemon K. Tan, and Maureen D. MayesARTHRITIS & RHEUMATISMVol. 54, No. 6, June...